

Product Name: CYT387 Revision Date: 01/10/2021

Product Data Sheet

CYT387

CYT387				
Cat. No.:	A4143			
CAS No.:	1056634-68-4			
Formula:	C23H22N6O2			
M.Wt:	414.46 N			
Synonyms:	Cyt-387,MOMELOTINIB,CYT 387,CYT 11387			
Target:	Chromatin/Epigenetics			
Pathway:	JAK			
Storage:	Store at -20°C			
	819			
Solvent & Solubility				

	insoluble in EtOH; ins	insoluble in EtOH; insoluble in H2O; \geq 20.7 mg/mL in DMSO				
In Vitro	Preparing Stock Solutions	Mass Solvent Concentration	1mg	5mg	10mg	
		1 mM	2.4128 mL	12.0639 mL	24.1278 mL	
		5 mM	0.4826 mL	2.4128 mL	4.8256 mL	
		10 mM	0.2413 mL	1.2064 mL	2.4128 mL	

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	JAK-1/-2 inhibitor,ATP competitive		
IC50 & Target	11 nM (JAK1), 18 nM (JAK2), 155 nM (JAK3)		
In Vitro	Cell Viability Assay		
	Cell Line:	Hematopoietic lines with JAK2V617F mutation; HEL cells with naturally acquired JAK2V617F; Baf3-EpoR-JAK2V617F cells.	
	Preparation method:	Soluble in DMSO > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.	
	Reacting conditions:	0.1-5 μM; 3 days.	
		1 www.apexbt.com	

	Applications:	In hematopoietic and somatic cell lines, CYT387 selectively inhibits JAK2-dependent cell growth and induces apoptosis. In Baf3-EpoR-JAK2V617F cells, CYT387 significantly inhibits cell growth and the phosphorylation of JAK2, extracellular signal-regulated kinase 1/2 (ERK1/2) and STAT5.		
	Animal experiment	310		
In Vivo	Animal models:	Mice with bone marrow transplantation.		
	Dosage form:	25, 50 mg/kg; twice daily at 10- to 12-hour intervals from day 34 after bone marrow transplantation to day 82; administrated orally.		
	Applications:	In Balb/c mice transplanted with bone marrow transduced with a JAK2V617F retrovirus, CYT387 reduces white cell counts and hematocrit. Also, CYT387 decreases granulocyte population and increases lymphocyte cell population. No change in body weight in CYT387-treated mice. CYT387 significantly reduces spleen size in both the 25 mg/kg and 50 mg/kg groups.		
	Preparation method:	Dissolved in NMP (120 mg/mL final; 1-methyl-2-pyrrolidinone). Subsequently the CYT387/NMP mix was diluted with 0.14M Captisol to a concentration of mg/mL and further diluted with 0.1M Captisol to a final concentration of mg/mL.		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.		

Product Citations



1. Cingöz O, Goff SP. "Cyclin-dependent kinase activity is required for type linterferon production." Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E2950-E2959.PMID:29507205

See more customer validations on www.apexbt.com.

References

[1]. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 2010, 115(25): 5232-5240.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage

2 | www.apexbt.com

temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



APExBIO Technology

www.apexbt.com 7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com





APEBN









